Omega Funds is a life sciences venture firm. Its own Purpose page states: "Founded in 2004, Omega Funds is a global leader in healthcare investing" and describes its work as "Creating and investing in life sciences companies that target our world's most urgent medical needs" across "oncology, immunology, rare diseases, precision medicine and others" (the firm's claims, quoted from its site). It both creates and invests in companies. It operates from 888 Boylston Street, Suite 1111, Boston, MA 02199 and Place du Molard 7, 1204 Geneva, Switzerland. Its December 2021 Fund VII announcement stated the firm had raised close to $2 billion since inception and that its portfolio companies had brought 46 products to market with 39 public listings and 35 M&A exits.
AUM66/100 Power Score™2004 FoundedBoston, MA
Life SciencesBiotechTherapeuticsHealthcarePharmaceuticals
Omega Funds is founded, per the firm's Purpose page: "Founded in 2004, Omega Funds is a global leader in healthcare investing".
2021
On 17 December 2021 Omega Funds announces the close of an oversubscribed $650 million Fund VII, above a $500 million target, and states it has raised close to $2 billion since inception.
2021
Francesco Draetta is promoted to Partner and Mike Powell joins as Executive Partner, announced alongside the Fund VII close on 17 December 2021.